Suchergebnisse - "Yang, Shenmiao"

PubPharm (49)

1

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

enthalten in: Investigational new drugs | 2023

von Song, Y. | Zhou, K. | Yang, S. | +17

2

Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia

enthalten in: Annals of hematology | 2023

von Yang, S. | Li, N. | Zhu, R. | +4

3

COVID-19 infection in patients with haematological malignancies : A single-centre survey in the latest Omicron wave in China

enthalten in: British journal of haematology | 2023

von Zhu, X. | Jiang, Q. | Lu, J. | +20

4

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

enthalten in: Investigational new drugs | 2023

von Song, Y. | Zhou, K. | Yang, S. | +17

5

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

enthalten in: Investigational new drugs | 2023

von Song, Y. | Zhou, K. | Yang, S. | +17

6

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

enthalten in: Investigational new drugs | 2023

von Song, Y. | Zhou, K. | Yang, S. | +17

7

Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia

enthalten in: Annals of hematology | 2023

von Yang, S. | Li, N. | Zhu, R. | +4

8

Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia

enthalten in: Annals of hematology | 2023

von Yang, S. | Li, N. | Zhu, R. | +4

9

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients : Multi-center, single-arm, open-label, phase 2 study

enthalten in: American journal of hematology | 2023

von Xu, W. | Zhou, K. | Wang, T. | +22

10

Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma : final results and correlative analysis of lymphocytosis

enthalten in: Leukemia & lymphoma | 2023

von Xu, W. | Yang, S. | Zhou, K. | +18

1
2
3
4
5
Nächster »
[5]